oncology
GI Cancer

New standard of care for hard-to-treat upper GI cancers

The addition of nivolumab to chemotherapy improves survival in patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. The phase 3 CheckMate 649 trial compared nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for unresectable non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, regardless of PD-ligand 1 (PD-L1) expression. The study, published in The Lancet, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic